Q32 Bio Inc. (NASDAQ:QTTB) Given Average Rating of “Moderate Buy” by Brokerages

Q32 Bio Inc. (NASDAQ:QTTB) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $29.86.

Several research analysts have recently commented on QTTB shares. Piper Sandler dropped their price target on shares of Q32 Bio from $85.00 to $20.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Leerink Partnrs lowered Q32 Bio from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Leerink Partners reiterated a “market perform” rating and set a $9.00 price target (down previously from $68.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. BMO Capital Markets cut their price objective on Q32 Bio from $64.00 to $22.00 and set an “outperform” rating on the stock in a research note on Thursday, December 12th. Finally, Raymond James restated an “outperform” rating and issued a $22.00 target price (down from $90.00) on shares of Q32 Bio in a report on Wednesday, December 11th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in QTTB. Values First Advisors Inc. bought a new stake in shares of Q32 Bio in the third quarter valued at approximately $33,000. Hussman Strategic Advisors Inc. bought a new stake in Q32 Bio in the 4th quarter valued at $36,000. Raymond James Financial Inc. acquired a new stake in Q32 Bio in the 4th quarter worth $37,000. Drive Wealth Management LLC bought a new position in shares of Q32 Bio during the 4th quarter worth about $38,000. Finally, Savant Capital LLC acquired a new position in shares of Q32 Bio during the fourth quarter valued at about $53,000. 31.32% of the stock is owned by institutional investors.

Q32 Bio Trading Down 0.3 %

NASDAQ:QTTB opened at $3.15 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 6.53 and a current ratio of 6.53. The company has a market capitalization of $38.37 million, a P/E ratio of -0.22 and a beta of -0.32. The stock’s 50 day moving average price is $6.86 and its 200 day moving average price is $29.27. Q32 Bio has a 52 week low of $2.90 and a 52 week high of $53.79.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.